Antengene Approved to Start China Trial of Endometrial Cancer Therapy

Antengene of Shanghai announced China approved a Phase III trial of selinexor (XPOVIO®) to treat advanced or recurrent endometrial cancer. Selinexor is an only-in-class oral selective inhibitor of nuclear export (SINE) that was discovered and developed by Karyopharm of Boston . In 2018, Antengene in-licensed greater China rights to Selinexor as part of a $162 million, four-drug deal. Selinexor is approved in the US to treat multiple myeloma and diffuse large B-cell lymphoma. More details... Stock Symbol: (HK: 6996) (NSDQ: KPTI) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.